The purpose of this study is to identify the most important, clinically significant patient-reported outcome (PRO) measures for chronic spontaneous urticaria and recurrent angioedema. In today’s patient-centered care, the use of PROs is becoming increasingly crucial. Several novel, validated, and trustworthy methods for assessing disease activity, disease control, and health-related quality of life impairment in patients with chronic spontaneous urticaria and recurrent angioedema have been available in recent years. These are necessary for clinical studies to be optimized and standardized. Furthermore, they are becoming more important in daily administration. The primary benefit of its use is that it not only improves and standardizes medical record-keeping and treatment, but it also frees up important time for genuine physician-patient consultations. However, the PROs must be properly integrated into patient management for this to function.

The currently available PRO measures can aid in better determining the patient’s illness condition, assisting in, documenting, and supporting treatment decisions, and improving the assessment of therapeutic effects. Many but not all languages now have linguistically verified versions of the PROs. More research is needed to fill these gaps in this area.

For latest news and updates

Reference:https://journals.lww.com/coallergy/Abstract/2015/06000/Clinically_relevant_outcome_measures_for_assessing.6.aspx